What is CNBX Pharms's earnings per share (EPS)?

CNBX Pharms (CNBX) reported diluted earnings per share of $0.00 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

CNBX Pharms Financials

CNBX

Source SEC Filings (10-K/10-Q) Updated Feb 28, 2026 Currency USD FYE August

This page shows CNBX Pharms (CNBX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 21 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CNBX FY2025 2026-04-22

Liquidity has collapsed as the company shrank spending and revenue while a liability load near $2.5M barely moved.

FY2024's smaller operating loss looked like improvement, but it came alongside revenue falling to about a third of FY2023 while SG&A and R&D were both cut sharply, so the business was retreating to lose less, not covering fixed costs more efficiently. That pattern continued later: share count expanded to 554.0M, yet cash was still only $15K, showing that balance-sheet relief did not arrive with the extra equity.

Cash losses were milder than accounting losses in FY2023 and FY2024, because operating cash outflow stayed well below the operating loss. That usually points to non-cash charges or working-capital effects cushioning the burn, but even after those offsets cash still fell from $130K to $26K over that span.

The balance sheet is being carried by liabilities, not assets: total assets dropped from $499K to $18K within two years. Meanwhile, current liabilities remained about $2.5M, leaving the current ratio effectively at zero rather than merely tight.

Financial Health Signals

Financial Profile 0/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of CNBX Pharms's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Growth

CNBX Pharms's revenue declined 100% year-over-year, from $130K to $0. This contraction results in a growth score of 0/100.

Liquidity

CNBX Pharms's current ratio of 0.01 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

YoY-100.0%

CNBX Pharms generated $0 in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior year.

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$0.00

CNBX Pharms earned $0.00 per diluted share (EPS) in fiscal year 2025. This represents an increase of 100.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$15K

YoY-42.8%

5Y CAGR-54.5%

10Y CAGR-5.0%

CNBX Pharms held $15K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

554M

CNBX Pharms had 554M shares outstanding in fiscal year 2025. This represents an increase of 1680.6% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

YoY-100.0%

CNBX Pharms invested $0 in research and development in fiscal year 2025. This represents a decrease of 100.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

CNBX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$0-100.0%	$130K-68.3%	$410K+1269.1%	$30K	$0-100.0%	$7K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$0-100.0%	$195K-54.9%	$432K-63.5%	$1.2M-33.2%	$1.8M+5.3%	$1.7M
SG&A Expenses	N/A	$518K-43.0%	$910K-49.5%	$1.8M+117.3%	$829K-36.7%	$1.3M
Operating Income	N/A	-$583K+37.4%	-$931K+68.5%	-$3.0M-13.6%	-$2.6M+14.6%	-$3.0M
Interest Expense	$46K+375.6%	-$17K	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	-$3.7M-16.6%	-$3.2M+57.2%	-$7.5M
EPS (Diluted)	$0.00	$-0.02+95.2%	$-0.42+88.3%	$-3.59	$-0.02	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$0	$0	N/A	$0	$0	$0	N/A	$0
Cost of Revenue	$0	N/A	N/A	N/A	$0	N/A	N/A	N/A
Gross Profit	$0	N/A	N/A	N/A	$0	N/A	N/A	N/A
R&D Expenses	$0	$0	N/A	$0	$0	$0	N/A	$43K
SG&A Expenses	$73K	N/A	N/A	$40K-37.6%	$65K+75.8%	$37K	N/A	$109K
Operating Income	-$73K	N/A	N/A	-$40K+37.6%	-$65K-75.8%	-$37K	N/A	-$152K
Interest Expense	N/A	$46K	N/A	N/A	N/A	$3K	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$44K	N/A	N/A	-$60K+14.4%	-$70K-103.2%	-$34K	N/A	-$131K
EPS (Diluted)	$0.00	$0.00	N/A	$0.00	$0.00	$-0.00	N/A	$0.00

CNBX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$18K-41.3%	$31K-93.7%	$499K-38.5%	$811K-73.7%	$3.1M+38.7%	$2.2M
Current Assets	$18K-41.3%	$31K-86.0%	$224K+13.1%	$198K-87.5%	$1.6M+71.1%	$930K
Cash & Equivalents	$15K-42.8%	$26K-79.6%	$130K+10.4%	$118K-91.5%	$1.4M+78.3%	$778K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.5M+0.1%	$2.5M-0.2%	$2.5M+406.4%	-$821K-164.5%	$1.3M+179.9%	$455K
Current Liabilities	$2.5M+0.1%	$2.5M-0.2%	$2.5M+3.0%	$2.4M+91.9%	$1.3M+179.9%	$455K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$2.5M-0.7%	-$2.5M-22.9%	-$2.0M-223.6%	$1.6M-9.6%	$1.8M+2.3%	$1.8M
Retained Earnings	-$25.3M-1.3%	-$25.0M-2.9%	-$24.3M-18.1%	-$20.5M-22.1%	-$16.8M-23.4%	-$13.6M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$15K+33.5%	$11K-39.5%	$18K-1.0%	$19K-63.3%	$51K+127.1%	$22K-28.9%	$31K-60.8%	$80K
Current Assets	$15K+33.5%	$11K-39.5%	$18K-1.0%	$19K-63.3%	$51K+127.1%	$22K-28.9%	$31K-60.8%	$80K
Cash & Equivalents	$12K+57.8%	$8K-49.0%	$15K+10.7%	$14K-70.1%	$46K+163.4%	$17K-34.4%	$26K-64.0%	$73K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.5M-1.4%	$2.6M+2.8%	$2.5M-1.6%	$2.6M-2.5%	$2.6M+3.3%	$2.5M+1.0%	$2.5M-0.9%	$2.5M
Current Liabilities	$2.5M-1.4%	$2.6M+2.8%	$2.5M-1.6%	$2.6M-2.5%	$2.6M+3.3%	$2.5M+1.0%	$2.5M-0.9%	$2.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$2.5M+1.5%	-$2.6M-3.1%	-$2.5M+1.6%	-$2.5M+1.3%	-$2.6M-2.2%	-$2.5M-1.4%	-$2.5M-1.0%	-$2.5M
Retained Earnings	-$25.4M-0.2%	-$25.4M-0.5%	-$25.3M-0.6%	-$25.1M-0.2%	-$25.1M-0.3%	-$25.0M-0.1%	-$25.0M-0.2%	-$24.9M

CNBX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	N/A	-$244K-117.1%	-$113K+93.3%	-$1.7M+32.6%	-$2.5M+10.2%	-$2.8M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$0-100.0%	$113K+359.4%	$25K-2.1%	$25K-96.1%	$645K-80.4%	$3.3M
Financing Cash Flow	N/A	$28K-72.5%	$100K-74.3%	$390K-84.1%	$2.5M	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$31K+35.6%	-$47K-66.1%	-$29K+45.1%	-$52K-0.7%	-$52K-32.2%	-$39K+19.0%	-$48K-21544.4%	$225
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	$0	$0	$0	$0	$0	$0-100.0%	$95K
Financing Cash Flow	$35K-12.5%	$40K+33.3%	$30K+50.1%	$20K-75.0%	$80K+166.7%	$30K+2281.0%	$1K+0.1%	$1K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CNBX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	-448.3%-221.2pp	-227.1%+9633.3pp	-9860.4%	N/A	-42524.1%
Net Margin	N/A	N/A	N/A	-12428.2%	N/A	-104337.9%
Return on Equity	N/A	N/A	N/A	-228.1%-51.2pp	-176.9%+246.3pp	-423.2%
Return on Assets	N/A	N/A	N/A	-459.0%-355.3pp	-103.8%+232.7pp	-336.5%
Current Ratio	0.010.0	0.01-0.1	0.090.0	0.08-1.2	1.25-0.8	2.04
Debt-to-Equity	-1.010.0	-1.01+0.2	-1.25-0.7	-0.50-1.2	0.70+0.4	0.26
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-296.0%	N/A	N/A	-320.8%-183.1pp	-137.8%+16.2pp	-154.0%	N/A	-163.2%
Current Ratio	0.010.0	0.000.0	0.010.0	0.01-0.0	0.02+0.0	0.010.0	0.01-0.0	0.03
Debt-to-Equity	-1.010.0	-1.000.0	-1.010.0	-1.01+0.0	-1.02-0.0	-1.010.0	-1.01+0.0	-1.03
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$2.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.01), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

PaxMedica, Inc. PXMD

$2.8M

Marizyme MRZM

$40K

Bassline Productions Inc BSSP

$37K

Itoco Inc ITMC

$41K

Navidea Biopharm NAVB

$50K

Frequently Asked Questions

What is CNBX Pharms's annual revenue?

CNBX Pharms (CNBX) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is CNBX Pharms's revenue growing?

CNBX Pharms (CNBX) revenue declined by 100% year-over-year, from $130K to $0 in fiscal year 2025.

What are CNBX Pharms's total assets?

CNBX Pharms (CNBX) had $18K in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does CNBX Pharms have outstanding?

CNBX Pharms (CNBX) had 554M shares outstanding as of fiscal year 2025.

What is CNBX Pharms's current ratio?

CNBX Pharms (CNBX) had a current ratio of 0.01 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is CNBX Pharms's debt-to-equity ratio?

CNBX Pharms (CNBX) had a debt-to-equity ratio of -1.01 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Why is CNBX Pharms's debt-to-equity ratio negative or unusual?

CNBX Pharms (CNBX) has negative shareholder equity of -$2.5M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is CNBX Pharms?

CNBX Pharms (CNBX) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.